Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment

Asparaginase (ASNase) is a biopharmaceutical for Acute Lymphoblastic Leukemia (ALL) treatment. However, it shows undesirable side effects such as short lifetimes, susceptibility to proteases, and immunogenicity. Here, ASNase encapsidation was genetically directed in bacteriophage P22-based virus-lik...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz-Barriga, Cristina, Villanueva-Flores, Francisca, Quester, Katrin, Zárate-Romero, Andrés, Cadena-Nava, Ruben Dario, Huerta-Saquero, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170886/
https://www.ncbi.nlm.nih.gov/pubmed/33922106
http://dx.doi.org/10.3390/pharmaceutics13050604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170886/
https://www.ncbi.nlm.nih.gov/pubmed/33922106
http://dx.doi.org/10.3390/pharmaceutics13050604

Ejemplares similares